Clinical Trials Arena on MSN
Alnylam reports preliminary Phase Ib trial results for brezosiran
The trial is designed to assess intrathecal doses of brezosiran in adults aged 25 to 70 years with genetically confirmed HD.
Medtronic and Johnson & Johnson presented new real-world and 12-month outcomes for their pulsed field ablation technologies ...
A new narrative review maps how troponin kinetics, inflammatory markers, natriuretic peptides, and emerging molecular ...
A Nature Reviews Cardiology review finds that centenarians typically delay rather than avoid cardiovascular disease, showing structural cardiac ageing alongside favourable metabolic, inflammatory, gut ...
Responses were deep and durable, with 65% ongoing at clinical cutoff; Results support continued evaluation of the ...
KEYTRUDA as Monotherapy Reduced Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent ...
Time is muscle” in ST-segment–elevation myocardial infarction (STEMI) is the foundational principle of STEMI care, but even ...
Alnylam Pharmaceuticals (NASDAQ:ALNY) outlined early clinical data for brezosiran, an investigational RNA interference ...
导语：血压数字只是冰山一角，醛固酮驱动的器官损伤才是水面下的真正威胁！在降压治疗手段不断丰富的今天，未控制及难治性高血压仍然是临床管理中的核心难题。对于这类患者，问题往往不只是血压数值未达标，更在于长期高血压暴露可能持续推动心血管、肾脏及其他靶器官损 ...
“Echocardiography is more than pressing a button to take pictures. It means reading blood flow and pressure in a constantly ...
Opracowanie podsumowuje stan wiedzy i przegląd publikacji dotyczących niewydolności serca za okres od 23.07.2025 r. do ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results